Velan Capital Investment Management LP Invests $2.09 Million in ADMA Biologics Inc $ADMA

Velan Capital Investment Management LP bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 250,000 shares of the biotechnology company’s stock, valued at approximately $2,092,000. ADMA Biologics makes up approximately 1.3% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 18th biggest position.

Several other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. acquired a new position in ADMA Biologics during the second quarter valued at approximately $321,037,000. State Street Corp grew its stake in ADMA Biologics by 0.3% during the fourth quarter. State Street Corp now owns 13,597,259 shares of the biotechnology company’s stock worth $248,014,000 after buying an additional 35,614 shares during the period. Sachem Head Capital Management LP increased its position in shares of ADMA Biologics by 27.0% in the fourth quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after acquiring an additional 2,415,000 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of ADMA Biologics by 36.9% in the 4th quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock valued at $127,551,000 after acquiring an additional 1,886,105 shares during the period. Finally, Capital Research Global Investors raised its stake in shares of ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after acquiring an additional 3,383,559 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $9.33 on Wednesday. The firm has a fifty day simple moving average of $9.10 and a 200-day simple moving average of $10.40. The company has a market capitalization of $2.09 billion, a PE ratio of 13.33 and a beta of 0.78. ADMA Biologics Inc has a twelve month low of $7.21 and a twelve month high of $20.46. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The firm had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. During the same quarter in the previous year, the firm posted $0.14 EPS. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. Equities research analysts anticipate that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Zacks Research lowered ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 4th. Raymond James Financial initiated coverage on ADMA Biologics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective on the stock. Canaccord Genuity Group decreased their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Mizuho lowered their target price on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $18.67.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.